ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,933Medicare Part D Prescriptions Filled, Including Refills

Rank: 43 out of 559

$430K Total Retail Price of All Prescriptions

Rank: 56 out of 559

579 Patients Receiving at Least One Drug in Part D
80%Patients 65 Years and Older
31% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Mexico
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 579 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

10% of this provider’s 579 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

3% of this provider’s 6,881 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

18% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$48 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

15 is the average number of prescriptions (including refills) per patient, compared to an average of 14.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Mexico
LEVOTHYROXINE SODIUM 566 514 1 2
LISINOPRIL 491 414 2 1
SIMVASTATIN 471 425 3 3
OMEPRAZOLE 360 274 4 4
AMLODIPINE BESYLATE 226 203 5 6
HYDROCODONE-ACETAMINOPHEN 199 113 S3 6 7
CITALOPRAM HBR 197 129 7 21
METOPROLOL SUCCINATE 188 132 8 16
ZOLPIDEM TARTRATE 181 165 9 17
GABAPENTIN 168 132 10 9
HYDROCHLOROTHIAZIDE 166 142 11 8
ATENOLOL 159 129 12 15
FLUTICASONE PROPIONATE 158 116 13 22
METFORMIN HCL 157 117 14 5
LOSARTAN POTASSIUM 144 127 15 14
LISINOPRIL-HYDROCHLOROTHIAZIDE 143 127 16 18
MORPHINE SULFATE ER 131 53 S2 17 63
LOVASTATIN 128 109 18 10
FUROSEMIDE 111 92 19 11
PANTOPRAZOLE SODIUM 108 82 20 41
SERTRALINE HCL 107 82 21 19
ALENDRONATE SODIUM 103 89 22 13
RANITIDINE HCL 98 61 23 26
OXYCODONE-ACETAMINOPHEN 95 35 S2 24 44
METOPROLOL TARTRATE 91 80 25 12
ATORVASTATIN CALCIUM 83 64 26 20
DIOVAN 80 68 27 55
PROAIR HFA 80 59 27 29
CYCLOBENZAPRINE HCL 76 50 R 29 54
TRAMADOL HCL 70 61 30 27
FLUOXETINE HCL 70 55 30 37
TRIAMTERENE-HCTZ 59 54 32 47
BACLOFEN 58 17 33 90
MELOXICAM 58 47 33 42
MIRTAZAPINE 58 58 33 61
DOXEPIN HCL 55 52 36 171
PREMARIN 54 48 R 37 97
POTASSIUM CHLORIDE 54 48 37 23
AMITRIPTYLINE HCL 53 49 R 39 58
CLONIDINE HCL 52 46 40 68
WARFARIN SODIUM 50 41 41 24
BUPROPION HCL SR 50 28 41 114
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 15, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.